|Mylan Signs Agreement with Gilead for Access to ARVs; ARIAD Pharma Q2 Net Loss Widens|
|By Staff and Wire Reports|
|Thursday, 02 August 2012 18:07|
Mylan Inc. (Nasdaq: MYL) announced the establishment of a new agreement between its subsidiary Mylan Laboratories Limited and Gilead Sciences (NASDAQ: GILD) Inc. Under this agreement, Mylan has licensed the rights to produce and market generic versions of Gilead HIV/AIDS therapies containing Emtricitabine, including single and fixed-dose combinations. Emtricitabine is marketed by Gilead under the brand name Emtriva®, and a fixed-dose combination of emtricitabine and tenofovir disoproxil fumarate is available under the brand name Truvada®. Emtricitabine also is a component of the "Quad," an investigational medicine that combines four Gilead medicines in a once-daily, single tablet regimen for the treatment of HIV-1 infection.
Mylan CEO Heather Bresch commented: "Access to affordable medicine continues to be an acute need in tackling HIV/AIDS, and once again we are delighted to be collaborating with Gilead in these efforts. Mylan is focused on expanding access to high-quality treatments to those in need around the world. Partnerships like this one ensure that patients in developing markets have access to important, recommended treatment options, like those containing emtricitabine."
ARIAD Pharmaceuticals Inc.'s (NASDAQ:ARIA) second-quarter net loss widened to $51.3 million, from $47.8 million in 2011, while loss per share narrowed to $0.31 from $0.36 last year. On average, 16 analysts polled by Thomson Reuters expected loss per share of $0.27 for the quarter. Analysts' estimates typically exclude one-time items.
Total revenue climbed to $318,000 from $66,000 in the previous year. Analysts estimated revenues of $1.93 million for the quarter.
As a consequence of not receiving the $25 million milestone payment from Merck related to U.S. approval of ridaforolimus in the sarcoma indication, offset in part by reduced expenses, 2012 guidance is being updated. ARIAD expects cash used in operations for 2012 to be in the range of $162 million - $167 million.
Acura Pharmaceuticals, Inc. (NASDAQ: ACUR) today announced its support for the Stop Tampering of Prescription Pills ("STOPP") Act of 2012, H.R. 6160, introduced by a bi-partisan group led by Representative William Keating (D-MA).
Alliqua, Inc. (OTCBB: ALQA) ("Alliqua" or the "Company"), an advanced biopharmaceutical company focused on the development, manufacturing and distribution of proprietary transdermal wound care and drug delivery technologies, today announced the Company has named Stephen A. Brigido, D.P.M. to serve as chairman for the Alliqua Scientific Advisory Board ("SAB").
Bioheart, Inc. (OTCBB: BHRT) announced today it has received a non-binding term sheet and investment offer in the amount of $ 2 million from Grupo Vitalmex in Mexico, a global leader in the healthcare sector in Latin America and Europe.
BioPower Operations Corporation (OTCQB: BOPO) today announced that its wholly-owned subsidiary FTZ Exchange has executed a Strategic Alliance with Capacity 360, LLC and Founder Tom Settineri to develop excess capacity transactions.
Discovery Laboratories, Inc. (Nasdaq: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today reports financial results for the second quarter ended June 30, 2012 and provides a business update.
Haemonetics Corporation (NYSE: HAE) today reported first quarter 2013 GAAP net revenue of $176.5 million, up 3%, net income of $9.8 million, down 42%, and diluted earnings per share of $0.38 down 42%.
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the Center for Biologics Evaluation and Research (CBER) of the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) for Baxter's HyQ Biologics License Application (BLA).
Mylan Inc. (Nasdaq: MYL) today applauded a new study released by the Generic Pharmaceutical Association (GPhA) as further evidence of the savings and access that high quality, cost effective generic prescription drugs can bring to American consumers.
Oncolytics Biotech Inc. (TSX:ONC, NASDAQ: ONCY) ("Oncolytics" or the "Company") today announced its financial results and operational highlights for the quarter ended June 30, 2012.
PAREXEL Consulting, a business unit of PAREXEL International (NASDAQ: PRXL) and a leading global consultancy serving the biopharmaceutical and medical device industries, today announced that Leanne R. Larson has been appointed as Vice President, Evidence Development.
Sigma-Aldrich®Corporation (Nasdaq: SIAL) today announced that Sigma Advanced Genetic Engineering (SAGE) Labs, an initiative of Sigma® Life Science and Autism Speaks®, the nation's largest autism science and advocacy organization, expanded a collaboration to develop the first rat models with modified autism associated genes, intended to accelerate discovery and translational autism research.